

## DAFTAR PUSTAKA

- Abdel-Misih, S. R. Z. and Bloomston, M. (2010) 'Liver Anatomy', *Surgical Clinics of North America*. Elsevier Ltd, 90(4), pp. 643–653. doi: 10.1016/j.suc.2010.04.017.
- Bruix, J. and Sherman, M. (2011) 'Management of hepatocellular carcinoma: An update', *Hepatology*, 53(3), pp. 1020–1022. doi: 10.1002/hep.24199.
- Dahlan, M.S. 2013. *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. 3rd ed. A. Suslia, ed. Jakarta: Salemba Medika.
- Edeline, J., Boucher, E., Rolland, Y., Vauléon, E., Pracht, M., Perrin, C., Le Roux, C. and Raoul, J. L. (2012) 'Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma', *Cancer*, 118(1), pp. 147–156. doi: 10.1002/cncr.26255.
- Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L. and Dodd, L. (2008) 'New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)', *European Journal of Cancer*. Elsevier Ltd, 45(2), pp. 228–247. doi: 10.1016/j.ejca.2008.10.026.
- El-Serag, H. B., Marrero, J. A., Rudolph, L. and Reddy, K. R. (2008) 'Diagnosis and Treatment of Hepatocellular Carcinoma', *Gastroenterology*, 134(6), pp. 1752–1763. doi: 10.1053/j.gastro.2008.02.090.
- El-Serag, H. B. and Rudolph, K. L. (2007) 'Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis', *Gastroenterology*, 132(7), pp. 2557–2576. doi: 10.1053/j.gastro.2007.04.061.
- Ellis, H. (2011) 'Anatomy of the liver', *Surgery*. Elsevier Ltd, 29(12), pp. 589–592. doi: 10.1016/j.mpsur.2011.09.012.
- Exhibit, E., Rabouhans, J. S., Baron, A., Cazejust, J. and Rosmorduc, O. (2011) 'A radiologist's guide to the modified Response Evaluation Criteria in Solid Tumours (mRECIST) assessment of therapy for hepatocellular carcinoma', *European Society of Radiology*, pp. 1–42.
- Fan, J., Wu, Z. Q., Tang, Z. Y., Zhou, J., Qiu, S. J., Ma, Z. C., Zhou, X. D. and Ye, S. L. (2001) 'Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein.', *World journal of gastroenterology: WJG*, 7(1), pp. 28–32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11819728>.

- Farazi, P. A. and DePinho, R. A. (2006) 'Hepatocellular carcinoma pathogenesis: From genes to environment', *Nature Reviews Cancer*, 6(9), pp. 674–687. doi: 10.1038/nrc1934.
- Ferlay, J., Soerjomataram I, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman D, D. and Bray, F. (2015) 'Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.', *Int J Cancer*, 136(5), pp. E359-386. doi: 10.1002/ijc.29210.
- Forner, A., Real, M. I., Varela, M. and Bruix, J. (2007) 'Transarterial chemoembolization for patients with hepatocellular carcinoma.', *Hepatology research*, 37 Suppl 2, pp. S230-7. doi: 10.1111/j.1872-034X.2007.00190.x.
- Fournier, L., Ammari, S. and Thiam, R. (2014) 'Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson', *Diagnostic and Interventional Imaging*. Elsevier Masson SAS, 95(7–8), pp. 689–703. doi: 10.1016/j.diii.2014.05.002.
- Georgiades, C. S., Hong, K., D'Angelo, M. and Geschwind, J.-F. H. (2005) 'Safety and Efficacy of Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma and Portal Vein Thrombosis', *Journal of Vascular and Interventional Radiology*, 16(12), pp. 1653–1659. doi: 10.1097/01.RVI.0000182185.47500.7A.
- Gonzalez-guindalini, F. D., Marcos, P., Salem, R. and Yaghmai, M. B. A. V. (2013) 'Assessment of Liver Tumor Response to Therapy: Role of', *Radiographics.rsna.org*, 33(6), pp. 1782–1800.
- Gouripur, G. C. and Kaliwal, B. B. (2013) 'Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management', *World Journal of Hepatology*, 9327(20), pp. 597–618. doi: 10.20959/wjpr2016-6447.
- Grandhi, M. S., Kim, A. K., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A. and Pawlik, T. M. (2016) 'Hepatocellular carcinoma: From diagnosis to treatment', *Surgical Oncology*. Elsevier Ltd, 25(2), pp. 74–85. doi: 10.1016/j.suronc.2016.03.002.
- Han, K. and Kim, J. H. (2015) 'Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system', *World Journal of Gastroenterology*, 21(36), pp. 10327–10335. doi: 10.3748/wjg.v21.i36.10327.
- Hyun, D., Shin, S. W., Cho, S. K., Park, K. B., Park, H. S., Choo, S. W., Do, Y. S., Choo, I. W., Shin, J. W. and Lim, S. J. (2015) 'Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma', *Acta Radiologica*, 56(12), pp. 1437–1445. doi: 10.1177/0284185114560937.

- Idée, J. M. and Guiu, B. (2013) 'Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review', *Critical Reviews in Oncology/Hematology*. Elsevier Ireland Ltd, 88(3), pp. 530–549. doi: 10.1016/j.critrevonc.2013.07.003.
- Jemal, A., Bray, F. and Ferlay, J. (1999) 'Global Cancer Statistics: 2011', *CA Cancer J Clin*, 49(2), p. 1,33-64. doi: 10.3322/caac.20107.Available.
- Kohla, M. A. S., Abu Zeid, M. I., Al-Warraky, M., Taha, H. and Gish, R. G. (2015) 'Predictors of hepatic decompensation after TACE for hepatocellular carcinoma', *BMJ Open Gastroenterology*, 2(1), p. e000032. doi: 10.1136/bmjgast-2015-000032.
- Lencioni, R. (2010) 'Loco-Regional Treatment of Hepatocellular Carcinoma', *Hepatology*, 52(2), pp. 762–773. doi: 10.1002/hep.23725.
- Maida, M., Cabibbo, G., Brancatelli, G., Genco, C., Alessi, N., Genova, C., Romano, P., Raineri, M., Giarratano, A., Midiri, M. and Cammà, C. (2013) 'Assessment of treatment response in hepatocellular carcinoma: a review of the literature', *Future Oncol*, 9(6), pp. 845–854.
- Meza-Junco, J., Montano-Loza, A. J., Liu, D. M., Sawyer, M. B., Bain, V. G., Ma, M. and Owen, R. (2012) 'Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?', *Cancer Treatment Reviews*. Elsevier Ltd, 38(1), pp. 54–62. doi: 10.1016/j.ctrv.2011.05.002.
- Padhya, K. T., Marrero, J. A. and Singal, A. G. (2013) 'Recent advances in the treatment of hepatocellular carcinoma', *Current Opinion in Gastroenterology*, 29(3), pp. 285–292. doi: 10.1097/MOG.0b013e32835ff1cf.
- Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P. (2002) 'Global cancer statistics, 2002', *CA: a cancer journal for clinicians*, 55(2), pp. 74–108. doi: 10.3322/canjclin.55.2.74.
- Pracht, M. (2012) 'Comparison of Tumor Response by Response Evaluation Criteria in Solid Tumors ( RECIST ) and Modified RECIST in Patients Treated With Sorafenib for Hepatocellular Carcinoma', *Cancer*, pp. 147–156. doi: 10.1002/cncr.26255.
- Rabouhans, J. S., Baron, a, Cazejust, J. and Rosmorduc, O. (2011) 'A radiologist's guide to the modified Response Evaluation Criteria in Solid Tumours (mRECIST) assessment of therapy for hepatocellular carcinoma', *European Society of Radiology Electronic Presentation Online System*, Poster C-2, pp. 1–42. doi: 10.1594/ecr2011/C-2120.
- Ramaiya, N. H. and Ad, A. (2011) 'Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know', *American Journal of Roentgenology*, 195(August 2010), pp. 281–289. doi:

10.2214/AJR.09.4110.

Ramsey, D. E., & Geschwind, J. F. H. (2004). Chemoembolization of unresectable hepatocellular carcinoma: A review. *Applied Radiology*, 33(3), 8.

Sanyal, A. J., Yoon, S. K. and Lencioni, R. (2010) 'The Etiology of Hepatocellular Carcinoma and Consequences for Treatment', *The Oncologist*, 15(Supplement 4), pp. 14–22. doi: 10.1634/theoncologist.2010-S4-14.

Sastroasmoro, S. & Ismael, S. 2011. Usulan Penelitian. In S. Sastroasmoro & S. Ismael, eds. *Dasar-dasar Metodologi Penelitian Klinis*. Jakarta: Sagung Seto, pp. 31–63.

Sato, Y., Watanabe, H., Sone, M., Onaya, H., Sakamoto, N., Osuga, K., Takahashi, M. and Arai, Y. (2013) 'Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602', *Upsala Journal of Medical Sciences*, 118(1), pp. 16–22. doi: 10.3109/03009734.2012.729104.

Schütte, K., Schulz, C. and Malfertheiner, P. (2014) 'Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment', *Gastrointestinal Tumors*, 1(2), pp. 84–92. doi: 10.1159/000362583.

Shim, J. H., Lee, H. C., Kim, S.-O., Shin, Y. M., Kim, K. M., Lim, Y.-S. and Suh, D. J. (2012) 'Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models', *Radiology*, 262(2), pp. 708–718. doi: 10.1148/radiol.11110282.

Shin, S. W. (2009) 'The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma', *Korean Journal of Radiology*, 10(5), p. 425. doi: 10.3348/kjr.2009.10.5.425.

Sieghart, W., Hucke, F. and Peck-Radosavljevic, M. (2015) 'Transarterial chemoembolization: Modalities, indication, and patient selection', *Journal of Hepatology*. European Association for the Study of the Liver, 62(5), pp. 1187–1195. doi: 10.1016/j.jhep.2015.02.010.

Waller, L. P., Deshpande, V. and Prysopoulos, N. (2015) 'Hepatocellular carcinoma: A comprehensive review', *World Journal of Hepatology*, 7(26), pp. 2648–2663. doi: 10.4254/wjh.v7.i26.2648.

Ye, S.-L., Takayama, T., Geschwind, J., Marrero, J. A. and Bronowicki, J.-P. (2010) 'Current Approaches to the Treatment of Early Hepatocellular Carcinoma', *The Oncologist*, 15(Supplement 4), pp. 34–41. doi: 10.1634/theoncologist.2010-S4-34.

Yeo, D. M., Choi, J. Il, Lee, Y. J., Park, M. Y., Chun, H. J. and Lee, H. G. (2014)

‘Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads’, *Journal of Computer Assisted Tomography*, 38(3), pp. 391–397. doi: 10.1097/RCT.0000000000000070.